Pasar al contenido principal

Tratamiento personalizado de la Acromegalia empleando la firma metabólica y estudios de imagen avanzados

PI22/01364

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

  • Marazuela, Mónica|||0000-0003-1158-9618
  • Martínez-Hernández, Rebeca
  • Marques-Pamies, Manuel
  • Biagetti, Betina|||0000-0002-8837-4343
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

  • Ruiz-Janer, Sabina|||0000-0002-8073-9504
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Biagetti, Betina|||0000-0002-8837-4343
  • Venegas, Eva
  • Cámara, Rosa|||0000-0002-3289-3400
  • García Centeno, Rogelio
  • Gálvez, María-Angeles
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Maraver, Silvia
  • González, Inmaculada
  • Abellán-Galiana, Pablo|||0000-0003-1221-3946
  • Trincado, Pablo
  • Herrera, Mayte T.
  • Olvera, Pilar
  • Xifra, Gemma
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Serra-Soler, Guillermo
  • Azriel, Sharona
  • García, Lourdes
  • Carvalho, Davide|||0000-0002-3156-3741
  • Jordà, Mireia|||0000-0003-3709-1850
  • Valassi, Elena|||0000-0002-3864-0105
  • Puig, Josep|||0000-0003-2791-6599
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Objective: Hyperintensity signal in T2-weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real-life clinical practice. Design, Patients and Measurements: Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2-weighted MRI signal at diagnosis was qualitatively classified as iso-hyperintense or hypointense. Insulin-like growth factor (IGF-I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered 'complete' when normalization of IGF-I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline. Results: Eighty-one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow-up, 42/73 cases (58%) showed normalization of IGF-I and 37% both GH and IGF-I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense. Conclusions: T2-signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF-I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Background and Aims: Predictors of first-generation somatostatin receptor ligands (fgSRLs) response in acromegaly have been studied for over 30 years, but they are still not recommended in clinical guidelines. Is there not enough evidence to support their use? This systematic review aims to describe the current knowledge of the main predictors of fgSRLs response and discuss their current usefulness, as well as future research directions. Methods: A systematic search was performed in the Scopus and PubMed databases for functional, imaging, and molecular predictive factors. Results: A total of 282 articles were detected, of which 64 were included. Most of them are retrospective studies performed between 1990 and 2023 focused on the predictive response to fgSRLs in acromegaly. The usefulness of the predictive factors is confirmed, with good response identified by the most replicated factors, specifically low GH nadir in the acute octreotide test, T2 MRI hypointensity, high Somatostatin receptor 2 (SSTR2) and E-cadherin expression, and a densely granulated pattern. Even if these biomarkers are interrelated, the association is quite heterogeneous. With classical statistical methods, it is complex to define reliable and generalizable cut-off values worth recommending in clinical guidelines. Machine-learning models involving omics are a promising approach to achieve the highest accuracy values to date. Conclusions: This survey confirms a sufficiently robust level of evidence to apply knowledge of predictive factors for greater efficiency in the treatment decision process. The irruption of artificial intelligence in this field is providing definitive answers to such long-standing questions that may change clinical guidelines and make personalized medicine a reality.